Rep. McAdams Backs Legislation to Speed Generic Medications to Market

December 4, 2019 by Dan McCue
Rep. Ben McAdams

WASHINGTON – While some continue to merely talk about the need to rein in prescription drug prices, Rep. Ben McAdams, D-Utah, has actually taken action on bipartisan legislation to help lower the cost of often life-changing medications.

Along with fellow members of the moderate Blue Dog Coalition, McAdams supported and got the House to pass the CREATES Act and BLOCKING Act, bills aimed at helping generic drug makers bring their products to market more quickly while also lifting barriers to competition.

“Generic drugs are as effective as brand-name equivalents but often cost much less and that means substantial savings for patients,” McAdams told The Well News.

H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, prohibits pharmaceutical and biologic companies from engaging in anti-competitive conduct that blocks lower-cost generic drugs from entering the market.

Meanwhile, H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, rewards manufacturers for challenging weak patents and bringing new generic drugs to the market by challenging generic drugs from parking patents for an extended period of time.

Current law awards 180 days of exclusivity on the market to a drug manufacturer when they are the first to file a generic drug application with the FDA for a drug for which there is no generic.

This 180-day clock starts when the generic only starts to market their drug. This BLOCKING Act would start the 180-day clock once a second generic drug files their patent.

The Blue Dog Coalition last month called on Congress to take up these and other prescription drug pricing bills that they believe, if considered individually, could pass a Democratic-led House and a Republican-led Senate.

Among the other bills endorsed by the group is one that would prohibit the practice of “pay-for-delay,” in which brand name drug companies compensate generics to delay the entry of generic drugs into the market, and others that would mandate greater transparency for patients, doctors, employers, and other buyers, in regard to drug pricing and the factors that influence what they pay at the pharmacy counter.

“Congress must deliver results on lowering the cost of life saving drugs for American families,” Rep. McAdams said. “Every month we delay means more hardship and health problems for seniors covered under Medicare Part D. It’s wrong that they are not able to fill their prescriptions or take them as prescribed, because they aren’t affordable.”

McAdams said health care on one of the most frequent topics that his constituents ask him about during town halls back in his district.

“Utahns expect us to rise above partisan politics and not let that stop us from getting this important work done,” he said.  “The House has taken up a number of bipartisan proposals aimed at making the drug market more competitive and drugs more affordable, which we absolutely can and must get into law this Congress.

“But it’s clear that we also need to fix the system more broadly.,” McAdams continued. “We have bipartisan support between the House, Senate, and Administration to take big steps like slowing the rapid rise of drug prices.  Capping seniors’ out-of-pocket costs in Medicare Part D plans is one of my top priorities – we can’t let seniors living on fixed incomes skip their insulin, heart medications, or cancer treatments because drug prices rise exponentially, and they’re left on the hook for more and more.” 

The representative noted that Sen. Mike Lee, R-Utah,  has taken the lead on getting the CREATES Act through the Senate and said he believes the bill could actually make it to the president’s desk.

“Both sides need to stop playing politics with drug prices,” McAdams said. “I came to Congress as an independent voice for my district, not beholden to any particular party or ideology … [and] it is impractical to think that either Democrats or Republicans must demand ‘their way or the highway.’” 

“Frankly, with all the debate about divisive issues, we should take an opportunity to solve high drug prices, an issue that both parties agree on and have some common ground on the solutions,” he said.  “I continue working with my colleagues on both sides of the aisle to prove we can deliver results and fix a broken Congress. 

“Americans in Democratic and Republican districts across the country can’t wait for Congressional leaders to retreat to their partisan corners when instead we can make progress by working together,” McAdams said.

Prescription Drugs

Amid Hope for Pfizer Vaccine, States Grapple with Distribution
State News
Amid Hope for Pfizer Vaccine, States Grapple with Distribution

A COVID-19 vaccine from Pfizer Inc. may be on the horizon, but the cost of distributing vaccines across all 50 states and who will pay for that operation remains a huge stumbling block. What is clear is that much of the financial burden and logistical challenge of getting... Read More

Pfizer Says COVID-19 Vaccine Appears to be 90% Effective
Health
Pfizer Says COVID-19 Vaccine Appears to be 90% Effective
November 9, 2020
by Dan McCue

Stocks surged around the world Monday after Pfizer announced that early results from trials of its coronavirus vaccine suggest the shots may be 90% effective at preventing COVID-19. But President-elect Joe Biden quickly reminded Americans that the good news does not mean it's time to abandon... Read More

Biden Advisers Met With Warp Speed Drugmakers Before Election
Health
Biden Advisers Met With Warp Speed Drugmakers Before Election

President-elect Joe Biden's health care advisers have held talks with pharmaceutical-industry executives in which they discussed Operation Warp Speed, the U.S. development program for coronavirus vaccines and treatments, according to people familiar with the matter. Biden advisers met with companies that have COVID-19 vaccines or therapies in late-stage clinical trials... Read More

Supreme Court Hears Drug Benefits Case with Wide-Ranging Impact
Prescription Drugs
Supreme Court Hears Drug Benefits Case with Wide-Ranging Impact

WASHINGTON — The Supreme Court heard arguments Tuesday on state regulation of prescription drug benefit companies in a case with potential impacts for health care across most of the country. Rutledge v. Pharmaceutical Care Management Association addresses a 2015 Arkansas law regulating how pharmacy benefit managers... Read More

Pharma Lobby Disputes Trump’s Claim That Drug Companies Are Negotiating
Prescription Drugs
Pharma Lobby Disputes Trump’s Claim That Drug Companies Are Negotiating

WASHINGTON — The pharmaceutical industry’s leading lobby group said Tuesday it did not know of a meeting at the White House to discuss lowering prescription drug prices, after President Donald Trump said executives were coming in this week to negotiate. “We are not aware of any... Read More

Trump to Require Government to Buy American When It Comes to 'Essential' Drugs
Prescription Drugs
Trump to Require Government to Buy American When It Comes to 'Essential' Drugs
August 6, 2020
by Dan McCue

WASHINGTON - President Donald Trump signed an executive order Thursday requiring the federal government to buy "essential" drugs from U.S. companies, a White House trade advisor said. “If we’ve learned anything from the China virus pandemic, it is that we are dangerously over-dependent on foreign nations... Read More

News From The Well
scroll top